{"organizations": [], "uuid": "02afe3dfa5b6b8b1c1c8e7869ead9d131b190e79", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "", "site_section": "http://www.reuters.com/finance/personal-finance", "section_title": "Wealth, Personal Finance &amp; Money | Reuters.com", "url": "http://www.reuters.com/article/2015/07/23/roche-results-idUSL5N1030F620150723", "country": "US", "title": "UPDATE 1-Roche first-half sales rise 3 pct, 2015 outlook confirmed", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "UPDATE 1-Roche first-half sales rise 3 pct, 2015 outlook confirmed | Reuters", "spam_score": 0.0, "site_type": "news", "published": "2015-07-23T09:34:00.000+03:00", "replies_count": 0, "uuid": "02afe3dfa5b6b8b1c1c8e7869ead9d131b190e79"}, "author": "Reuters", "url": "http://www.reuters.com/article/2015/07/23/roche-results-idUSL5N1030F620150723", "ord_in_thread": 0, "title": "UPDATE 1-Roche first-half sales rise 3 pct, 2015 outlook confirmed", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "(Adds CEO comment, detail on drugs)\nJuly 23 (Reuters) - Switzerland's Roche posted a slightly better-than-expected 3 percent year-on-year rise in first-half sales on Thursday as demand for its oncology drugs helped offset the strength of the Swiss franc.\nInvestors are banking on Roche's ability to retain its market-leading position in cancer medicine as it advances into the hot new field of immunotherapy, where it faces rivals such as Bristol-Myers Squibb and Merck.\n\"We have made significant progress in cancer immunotherapy and now have over 40 programmes in clinical development,\" Roche Chief Executive Severin Schwan said.\nAt constant exchange rates, sales rose 6 percent and Schwan said he was pleased by the performance of non-cancer products such as Esbriet, a drug for a fatal lung condition that Roche acquired when it bought InterMune for $8.3 billion last August.\nThe company is also stepping up work on Alzheimer's disease.\nThe group needs to keep producing new products to counter the threat posed by cheap copies of biotech drugs, known as biosimilars, as well as innovative competition to eye drug Lucentis and hepatitis C treatment Pegasys.\nIts three top-selling cancer drugs - Herceptin, Rituxan and Avastin - are all still growing but the patents on the first two have already expired in Europe, clearing the way for biosimilars in the next couple of years.\nRoche reiterated its forecast for 2015 sales to grow in the low-to-mid single-digit range, after stripping out currency fluctuations, with core earnings per share (EPS) growing faster.\nGroup sales in the half year of 23.6 billion Swiss francs ($24.6 billion) generated core earnings per share (EPS) down 5 percent at 7.22 francs.\nAnalysts in a Reuters poll had forecast sales of 23.5 billion francs and core EPS of 7.35 francs. ($1 = 0.9586 Swiss francs) (Reporting by Ben Hirschler and Joshua Franklin ; Editing by Shri Navaratnam and Alan Raybould )", "external_links": [], "published": "2015-07-23T09:34:00.000+03:00", "crawled": "2015-07-23T08:42:12.198+03:00", "highlightTitle": ""}